Dr. Burtness on Immunotherapy and Radioresistance in Head and Neck Cancer

Barbara Burtness, MD
Published: Wednesday, Jul 19, 2017



Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

In an investigator-initiated trial at Yale Cancer Center, patients with persistent disease after radiation are being exposed to pembrolizumab (Keytruda) in hope of initiating an immune response prior to salvage therapy.
 


Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

In an investigator-initiated trial at Yale Cancer Center, patients with persistent disease after radiation are being exposed to pembrolizumab (Keytruda) in hope of initiating an immune response prior to salvage therapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x